Literature DB >> 26346639

Social Stress and Psychosis Risk: Common Neurochemical Substrates?

Romina Mizrahi1.   

Abstract

Environmental risk factors have been implicated in the etiology of psychotic disorders, with growing evidence showing the adverse effects of migration, social marginalization, urbanicity, childhood trauma, social defeat, and other adverse experiences on mental health in vulnerable populations. Collectively, social stress may be one mechanism that could link these environmental risk factors. The exact mechanism(s) by which social stress can affect brain function, and in particular the molecular targets involved in psychosis (such as the dopaminergic (DA) system), is (are) not fully understood. In this review, we will discuss the interplay between social environmental risk factors and molecular changes in the human brain; in particular, we will highlight the impact of social stress on three specific neurochemical systems: DA, neuroinflammation/immune, and endocannabinoid (eCB) signaling. We have chosen the latter two molecular pathways based on emerging evidence linking schizophrenia to altered neuroinflammatory processes and cannabis use. We further identify key developmental periods in which social stress interacts with these pathways, suggesting window(s) of opportunities for novel interventions. Taken together, we suggest that they may have a key role in the pathogenesis and disease progression, possibly provide novel treatment options for schizophrenia, and perhaps even prevent it.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26346639      PMCID: PMC4707841          DOI: 10.1038/npp.2015.274

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  115 in total

1.  Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison.

Authors:  J van Os; M Hanssen; R V Bijl; W Vollebergh
Journal:  Arch Gen Psychiatry       Date:  2001-07

2.  Prevalence and background factors of depression in first admitted schizophrenic patients.

Authors:  R Bottlender; A Strauss; H J Möller
Journal:  Acta Psychiatr Scand       Date:  2000-02       Impact factor: 6.392

3.  Meta-analysis of regional brain volumes in schizophrenia.

Authors:  I C Wright; S Rabe-Hesketh; P W Woodruff; A S David; R M Murray; E T Bullmore
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

4.  Effects of acute metabolic stress on striatal dopamine release in healthy volunteers.

Authors:  C M Adler; I Elman; N Weisenfeld; L Kestler; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  2000-05       Impact factor: 7.853

5.  Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment.

Authors:  J Boydell; J van Os; K McKenzie; J Allardyce; R Goel; R G McCreadie; R M Murray
Journal:  BMJ       Date:  2001-12-08

6.  Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia.

Authors:  D J Walder; E F Walker; R J Lewine
Journal:  Biol Psychiatry       Date:  2000-12-15       Impact factor: 13.382

Review 7.  Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies.

Authors:  M Laruelle; A Abi-Dargham
Journal:  J Psychopharmacol       Date:  1999-12       Impact factor: 4.153

8.  Proceedings: Alterations in dopamine uptake in rat corpus striatum induced by combinations of stress and delta8-tetrahydrocannabinol (delta8-THC).

Authors:  J M Littleton; K I Maclean; G Brownlee
Journal:  Br J Pharmacol       Date:  1976-03       Impact factor: 8.739

9.  Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study.

Authors:  Elaine F Walker; Hanan D Trotman; Brad D Pearce; Jean Addington; Kristin S Cadenhead; Barbara A Cornblatt; Robert Heinssen; Daniel H Mathalon; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Tyrone D Cannon; Thomas H McGlashan; Scott W Woods
Journal:  Biol Psychiatry       Date:  2013-04-03       Impact factor: 13.382

10.  Striatal dopamine release in schizophrenia comorbid with substance dependence.

Authors:  J L Thompson; N Urban; M Slifstein; X Xu; L S Kegeles; R R Girgis; Y Beckerman; J M Harkavy-Friedman; R Gil; A Abi-Dargham
Journal:  Mol Psychiatry       Date:  2012-08-07       Impact factor: 15.992

View more
  17 in total

1.  Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum.

Authors:  Christin Schifani; Sina Hafizi; Huai-Hsuan Tseng; Cory Gerritsen; Miran Kenk; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi
Journal:  Schizophr Res       Date:  2018-11-06       Impact factor: 4.939

2.  Transcriptome Alterations in Prefrontal Pyramidal Cells Distinguish Schizophrenia From Bipolar and Major Depressive Disorders.

Authors:  Dominique Arion; Zhiguang Huo; John F Enwright; John P Corradi; George Tseng; David A Lewis
Journal:  Biol Psychiatry       Date:  2017-04-04       Impact factor: 13.382

3.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

4.  What causes psychosis? An umbrella review of risk and protective factors.

Authors:  Joaquim Radua; Valentina Ramella-Cravaro; John P A Ioannidis; Abraham Reichenberg; Nacharin Phiphopthatsanee; Taha Amir; Hyi Yenn Thoo; Dominic Oliver; Cathy Davies; Craig Morgan; Philip McGuire; Robin M Murray; Paolo Fusar-Poli
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

5.  Linking Salience Signaling With Early Adversity and Affective Distress in Individuals at Clinical High Risk for Psychosis: Results From an Event-Related fMRI Study.

Authors:  Zachary B Millman; Jason Schiffman; James M Gold; LeeAnn Akouri-Shan; Caroline Demro; John Fitzgerald; Pamela J Rakhshan Rouhakhtar; Mallory Klaunig; Laura M Rowland; James A Waltz
Journal:  Schizophr Bull Open       Date:  2022-06-17

6.  Perceived stress influences anhedonia and social functioning in a community sample enriched for psychosis-risk.

Authors:  Andrea Pelletier-Baldelli; Gregory P Strauss; Franchesca S Kuhney; Charlotte Chun; Tina Gupta; Lauren M Ellman; Jason Schiffman; Vijay A Mittal
Journal:  J Psychiatr Res       Date:  2021-01-11       Impact factor: 4.791

7.  Ethnic Minority Status, Age-at-Immigration and Psychosis Risk in Rural Environments: Evidence From the SEPEA Study.

Authors:  James B Kirkbride; Yasir Hameed; Konstantinos Ioannidis; Gayatri Ankireddypalli; Carolyn M Crane; Mukhtar Nasir; Nikolett Kabacs; Antonio Metastasio; Oliver Jenkins; Ashkan Espandian; Styliani Spyridi; Danica Ralevic; Suneetha Siddabattuni; Ben Walden; Adewale Adeoye; Jesus Perez; Peter B Jones
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

8.  Quantitative exploration of factors influencing psychotic disorder ailments in Nigeria.

Authors:  Adebowale O Adejumo; Nehemiah A Ikoba; Esivue A Suleiman; Hilary I Okagbue; Pelumi E Oguntunde; Oluwole A Odetunmibi; Obalowu Job
Journal:  Data Brief       Date:  2017-07-24

9.  Interaction of childhood urbanicity and variation in dopamine genes alters adult prefrontal function as measured by functional magnetic resonance imaging (fMRI).

Authors:  Jessica L Reed; Enrico D'Ambrosio; Stefano Marenco; Gianluca Ursini; Amanda B Zheutlin; Giuseppe Blasi; Barbara E Spencer; Raffaella Romano; Jesse Hochheiser; Ann Reifman; Justin Sturm; Karen F Berman; Alessandro Bertolino; Daniel R Weinberger; Joseph H Callicott
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

10.  Inconclusive Evidence in Support of the Dopamine Hypothesis of Psychosis: Why Neurobiological Research Must Consider Medication Use, Adjust for Important Confounders, Choose Stringent Comparators, and Use Larger Samples.

Authors:  Michael P Hengartner; Joanna Moncrieff
Journal:  Front Psychiatry       Date:  2018-05-01       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.